Daily Brief ECM: IPO Databook: Daré Bioscience (DARE US) – Aug 2026 and more

• Daré Bioscience, Inc. is a purpose-driven health biotech company solely focused on women’s health, advancing innovations from contraception to infectious disease. It uses a dual-path approach for new products.
• DARE to PLAY Sildenafil Cream is the first 503B product, available for pre-order in December 2025, with revenue expected Q3 2026. Flora Sync LF5 launched June 2026, and Ovaprene is.
• The auditor’s report expresses substantial doubt about the company’s ability to continue as a going concern. Stockholders’ equity was less than $2.5 million as of March 31, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• RZ Wellness Limited, a Nevada corporation, operates through its Malaysian subsidiary, RZ Wellness Sdn. Bhd., selling dietary supplements and offering packaging and labeling solutions.
• The global dietary supplement and wellness market is projected to reach USD 7.43 trillion in 2026, with the dietary supplements market reaching USD 307.8 billion by 2028.
• A cash balance of $12,763 as of March 31, 2026, is not sufficient to fund operations for any period.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Zenshine Pharmaceuticals, founded in 2018, is a commercial-stage biopharmaceutical company developing therapeutics for viral infectious diseases, oncology, and inflammatory disorders. Its core product, sebaloxavir marboxil tablets, received NMPA approval.
• Zenshine’s core product, sebaloxavir marboxil tablets, was approved for adult influenza in July 2025 and adolescent influenza in June 2026.
• The company reported a loss of RMB209,268 thousand in 2025 and net liabilities of RMB(1,105,421) thousand as of June 30, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.